Home › Leiomyosarcoma › Illinois › Chicago
Leiomyosarcoma clinical trials in Chicago, IL
4 studies for Leiomyosarcoma are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
RecruitingPhase 1
- University of Chicago Comprehensive Cancer Center, Chicago
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
RecruitingPhase 2
- Northwestern University, Chicago
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RecruitingPhase 3
- Rush University Medical Center, Chicago
- University of Illinois at Chicago MBCCOP, Chicago
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RecruitingPhase 1/2
- Lurie Children's Hospital of Chicago, Chicago
Leiomyosarcoma trials in other cities
- Houston, TX7 studies
- Boston, MA5 studies
- New York City, NY4 studies
- Santa Monica, CA4 studies
- Nashville, TN3 studies
- Ann Arbor, MI3 studies
- Rochester, MN3 studies
- Columbus, OH3 studies
- Miami, FL3 studies
- Queens, NY3 studies
- St. Louis, MO3 studies
- Aurora, CO3 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.